Effect of O6-methylguanine-DNA methyltransferase methylation in medulloblastoma.

about

Effect of O6-methylguanine-DNA methyltransferase methylation in medulloblastoma.

Item

http://www.wikidata.org/entity/Q47128186

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Effect of O6-methylguanine-DNA methyltransferase methylation in medulloblastoma.

@en

Effect of O6-methylguanine-DNA methyltransferase methylation in medulloblastoma.

@nl

type

Item

label

Effect of O6-methylguanine-DNA methyltransferase methylation in medulloblastoma.

@en

Effect of O6-methylguanine-DNA methyltransferase methylation in medulloblastoma.

@nl

prefLabel

Effect of O6-methylguanine-DNA methyltransferase methylation in medulloblastoma.

@en

Effect of O6-methylguanine-DNA methyltransferase methylation in medulloblastoma.

@nl

P1476

Effect of O6-methylguanine-DNA methyltransferase methylation in medulloblastoma.

@en

P2093

Akihide Kondo

http://www.w3.org/2001/XMLSchema#string

Atsushi Arakawa

http://www.w3.org/2001/XMLSchema#string

Hajime Arai

http://www.w3.org/2001/XMLSchema#string

Ikuko Ogino

http://www.w3.org/2001/XMLSchema#string

Junya Fujimura

http://www.w3.org/2001/XMLSchema#string

Tomoko Kurimoto

http://www.w3.org/2001/XMLSchema#string

Toshiaki Shimizu

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular subgroups of medulloblastoma: the current consensus

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group.

Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study

Temozolomide is an active agent in children with recurrent medulloblastoma/primitive neuroectodermal tumor: an Italian multi-institutional phase II trial.

Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region.

MGMT: its role in cancer aetiology and cancer therapeutics.

Intercellular heterogeneity of expression of the MGMT DNA repair gene in pediatric medulloblastoma.

Outcome of children with metastatic medulloblastoma treated with carboplatin during craniospinal radiotherapy: a Children's Oncology Group Phase I/II study.

Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.

P304

1107-1111

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3892/MCO.2017.1431

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29285383

http://www.w3.org/2001/XMLSchema#string

P921

medulloblastoma

P932

5740829

http://www.w3.org/2001/XMLSchema#string